6 completed. 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 6 |
Follow Recurrent Cancer: new trials by email Literature Review of Recurrent Cancer trials Research Report on Recurrent Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conventional Therapy SNK02 - Pathologically Confirmed Cancer Refractory to Conventional Therapy, Refractory Cancer | Phase 1 | Completed | NKGen Biotech, Inc. | 6 | 2023-08-23 | 2024-11-20 |
| Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors CEA CAR-T cells - Colorectal Cancer, Esophageal Cancer | Phase 1 | Completed | Chongqing Precision Biotech Co., Ltd | 30 | 2021-09-10 | 2026-07-09 |
| Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients XRD-0394, Palliative radiotherapy - Metastasis, Locally Advanced Solid Tumor | Phase 1 | Completed | XRad Therapeutics Inc | 12 | 2021-08-24 | 2024-01-11 |
| Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy SNK01, Avelumab, Pembrolizumab - Refractory Cancer, Metastatic Cancer | Phase 1 | Completed | NKGen Biotech, Inc. | 27 | 2019-07-15 | 2023-11-13 |
| TCR-engineered T Cells in Solid Tumors: IMA202-101 IMA202 Product, IMADetect® - Solid Tumor, Adult, Refractory Cancer | Phase 1 | Completed | Immatics US, Inc. | 16 | 2019-05-02 | 2025-02-04 |
| IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors IRX 2, Nivolumab - Metastatic Cancer, Recurrent Cancer | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 12 | 2019-02-13 | 2023-04-14 |
Recurrence (6) · Neoplasm Metastasis (5) · Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinoma, Squamous Cell (1) · Carcinoma, Transitional Cell (1) · Colorectal Neoplasms (1) · Esophageal Neoplasms (1) · Pancreatic Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1) · Stomach Neoplasms (1)
Disease Attributes (6) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Neoplastic Processes (5) · Head and Neck Neoplasms (2) · Neoplasms (2) · Neoplasms by Site (2) · Adenocarcinoma (1) · Bronchial Neoplasms (1) · Carcinoma (1) · Carcinoma, Bronchogenic (1) · Colonic Diseases (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Endocrine Gland Neoplasms (1)
IRX 2 (1) · Nivolumab (1) · avelumab (1) · pembrolizumab (1)
NKGen Biotech, Inc. (2) · Chongqing Precision Biotech Co., Ltd (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Immatics US, Inc. (1) · XRad Therapeutics Inc (1)
United States (5) · China (1) · Germany (1)
Cedrik Britten, MD (1) · Jingwang Bi, M.D (1) · Paul Chang, MPH (1) · Rohit Jain, MD, MPH (1)